Janssen v. Celltrion: District Court Schedules Hearing on Motion to Dismiss

Janssen v. Celltrion (infliximab)

As we previously reported, Celltrion has moved to dismiss Janssen’s claim of infringement of the ’083 patent, the sole remaining patent in the case since the district court entered partial final judgment with respect to the ’471 patent.  On October 7, 2016, Judge Wolf issued an order instructing the parties, among other things, to continue to meet and confer and that, if Celltrion does not withdraw its motion to dismiss, a hearing on the motion will be held on December 21-22, 2016.  The order also provided further instructions about the parties’ pretrial submissions and additional pretrial conferences and reaffirmed that trial will begin on February 13, 2017.  According to the case docket, 10 days between February 13 and 24 are currently reserved for the jury trial, though the court’s order instructs the parties to include a statement in their January 12, 2017 pretrial memorandum of the number of trial days the trial will require, to aid the court in establishing time limits.

Stay tuned to Big Molecule Watch for further updates about this case.

Download PDF

Comments are closed.